CN1557387A - Aromatic turmeric oil extracts and its preparing process and medicinal composition containing the same - Google Patents
Aromatic turmeric oil extracts and its preparing process and medicinal composition containing the same Download PDFInfo
- Publication number
- CN1557387A CN1557387A CNA2004100138925A CN200410013892A CN1557387A CN 1557387 A CN1557387 A CN 1557387A CN A2004100138925 A CNA2004100138925 A CN A2004100138925A CN 200410013892 A CN200410013892 A CN 200410013892A CN 1557387 A CN1557387 A CN 1557387A
- Authority
- CN
- China
- Prior art keywords
- oleum curcumae
- extract
- oleum
- pharmaceutical composition
- silica gel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The zedoary extractive is prepared with zedoary oil as material and through chromatography with silica gel column, and contains curdione 30-60 wt%, elemenone 15-40 wt%, neo-curdione 1-15 wt%, curcumenol1-20 wt% and no instable benzofuran derivative. The zedoary extractive has high effect, less side effect and high stability, and may be mixed with different medicine carrier to prepare various medicine preparations, such as capsule and injection, for treating viral diseases, cardiac and cerebral vascular diseases and tumor.
Description
Technical field
The invention belongs to effective ingredient in Chinese and preparation method thereof, be specially Chinese medicine Oleum Curcumae extract and preparation method thereof and the pharmaceutical composition that contains this Oleum Curcumae extract
Background technology
Clinical antiviral drugs commonly used has at present: preventing respiratory viruses medicine ribavirin (RBV), amantadine, polyinosini; Anti-herpesvirus medicament acyclovir (ACV), ganciclovir (GCV), foscarnet sodium; Non-specific antiviral drugs interferon etc.Wherein RBV is better to rsv infection, but long-term heavy dose of application can cause reversibility anemia, WBC decline, abnormal liver function and gastrointestinal untoward reaction; Amantadine is only effective to the influenza virus A type; Polyinosini can suppress duplicating of viral RNA, and the inducement interferon ability is arranged, and is mainly used in the control of acute respiratory infection; ACV is better to herpes simplex virus, and GCV is to the cytomegalovirus determined curative effect, and is expected to be used for the treatment of Epstein-Barr virus and adenovirus infection, but both all can cause nervous system side effect such as drowsiness, hallucination, baby, the careful usefulness of old man such as tremble; The foscarnet sodium antiviral spectrum is wider, and untoward reaction is mainly renal damage, at present only as three-way drug use; The no direct antivirus action of interferon itself, main by combining with the specific receptor of cell surface, inducing cell produces a kind of antiviral protein and plays a role, and untoward reaction has heating, headache, weak etc.Therefore, exploitation antiviral drugs safe and effective, easy to use is significant.
Oleum Curcumae is the volatile oil that zingiberaceous plant Rhizoma Curcumae, Guangxi zedoary or RADIX CURCUMAE rhizome obtain through steam distillation, mainly contain curdione, curcumenol etc., has tangible antivirus action, Zedoary turmeric oil glucose injection as antiviral agents in clinical practice for many years, and record in the Pharmacopoeia of the People's Republic of China (two ones, 2000 editions).The Oleum Curcumae antiviral is safe and effective, can be used for children's and old man, and has a good antitumor effect, but its complicated component, zest is strong, poor stability, especially wherein contain the unsettled chemical constituent of auroral poles, very easily change, make that the quality of the pharmaceutical preparations is difficult to guarantee, influenced the effect of Oleum Curcumae clinical treatment.
Summary of the invention
The objective of the invention is to solve shortcomings such as complicated component, poor stability, zest that Oleum Curcumae exists are strong, the preparation effect is strong, side effect is little, the Oleum Curcumae extract of good stability, it is the compositions of the active constituent composition of Oleum Curcumae, and with this component as effective ingredient, mix with pharmaceutically acceptable carrier, preparation can be treated all kinds of preparations of viral disease, cardiovascular and cerebrovascular disease and tumor.
For addressing the above problem, the present invention proposes following technical scheme.
A kind of Oleum Curcumae extract by weight percentage, contains curdione 30-60%, elemi ketone 15-40%, (-)-Neocurdione 1-15%, curcumenol 1-20%; Described Oleum Curcumae extract by weight percentage, can contain curdione 35-55%, elemi ketone 20-35%, (-)-Neocurdione 2-10%, curcumenol 5-15%; Do not contain in the Oleum Curcumae extract importantly of the present invention or be substantially free of 6-methene methylene-4,5,6,7-tetrahydrochysene-3,6-dimethyl-5-isopropenyl-trans-benzofuran, because this chemical compound is a kind of photosensitive material, very easily oxidation, not only influence stability of formulation, and can produce stimulation in use.
Aforementioned Oleum Curcumae preparation method of extract, Oleum Curcumae and silica gel are mixed thoroughly, the silica gel consumption of mixing Oleum Curcumae be Oleum Curcumae 1-20 doubly, through silica gel column chromatography, eluting solvent be selected from petroleum ether, n-hexane, dichloromethane, ethyl acetate, chloroform, methanol or acetone wherein one or both.In the preparation method preferably of Oleum Curcumae extract, the silica gel consumption of mixing Oleum Curcumae is 2-10 a times of Oleum Curcumae, uses the petroleum ether eluting earlier, and the reuse eluent ethyl acetate is collected the eluent ethyl acetate part, except that after desolvating, gets pale brown color grease.
The present invention includes the pharmaceutical composition that contains the Oleum Curcumae extract, wherein contain among the claim 1-3 that treats effective dose each Oleum Curcumae extract and pharmaceutically acceptable carrier.
The pharmaceutical composition that contains the Oleum Curcumae extract, specifically can be: mainly form capsule 's content by Oleum Curcumae extract 5-200 part and vegetable oil 10-400 part by weight, wrap up in outward by glycerol: gelatin: water be with 1: 2-5: the capsule shell that 2-5 part weight ratio is made.
The pharmaceutical composition that contains the Oleum Curcumae extract preferably is: capsule 's content is mainly by Oleum Curcumae extract 10-100 part and vegetable oil 20-200 part are formed by weight.Described vegetable oil can be edible peanut oil, vegetable oil, Semen setariae wet goods, preferably meets the refining of edible vegetable oil of State Standard of the People's Republic of China GB15197-94.
The pharmaceutical composition that contains the Oleum Curcumae extract can also be: mainly by Oleum Curcumae extract 0.05-3 part, tween 80 0.05-3 part, water for injection are formed for 100 parts by weight; Its preferably proportioning be: form for 100 parts by Oleum Curcumae extract 0.1-1 part, tween 80 0.1-1 part, water for injection.
With the Oleum Curcumae is raw material, through silica gel column chromatography, behind the petroleum ether eluting, collect the eluent ethyl acetate part, the pale brown color grease of gained promptly is the Oleum Curcumae active constituent after vacuum reclaims ethyl acetate, it is characterized by the 6-methene methylene-4 that does not contain poor stability, 5,6,7-tetrahydrochysene-3,6-dimethyl-5-isopropenyl-trans-benzofuran composition, (the silica gel column chromatography developing solvent is the TLC of vanillin concentrated sulphuric acid colour developing: petroleum ether: ethyl acetate=9: 1) analyze demonstration four brownish red principal spots, wherein curdiones, elemi ketone, the ratio of (-)-Neocurdione and curcumenol is 30-60%: 15-40%: 1-15%: 1-20%.This Oleum Curcumae extract mixes with pharmaceutical carriers can prepare soft capsule or injection, cardio-cerebrovascular disorders such as treatment hypertension, cerebral thrombosis.
Oleum Curcumae extract main component involved in the present invention is clear, zest reduces, the reaction of mouse stomach 120mg/Kg no abnormality seen; Drug action strengthens, observation in vitro Oleum Curcumae active constituent is to anti-/ 0185 strain in influenza virus A/ capital, the antivirus action of respiratory syncytial virus Long strain, the virus host cell is Madin-Darby canine kidney(cell line) (MDCK) (TDCK) and people's laryngeal cancer cell (Hep-2), culture medium is RPMI-1640, and Oleum Curcumae active constituent and Oleum Curcumae are respectively 1.16 μ g/ml and 1.95 μ g/ml to anti-/ 0185 strain medium effective concentration in influenza virus A/ capital; Respiratory syncytial virus Long strain virus medium effective concentration is respectively 4.37 μ g/ml and 7.59 μ g/ml, shows that Oleum Curcumae extract drug action of the present invention strengthens; Side effect is little, LD50＞200mg/Kg; Good stability has especially been removed wherein to the unsettled 6-methene of auroral poles methylene-4,5,6,7-tetrahydrochysene-3,6-dimethyl-5-isopropenyl-trans-benzofuran, with 4500 ± 500 LX illumination 10 days, outward appearance did not have significant change, makes the quality of the pharmaceutical preparations be guaranteed.The compositions that the active ingredient that Oleum Curcumae extract of the present invention is an Oleum Curcumae is formed, is mixed with pharmaceutically acceptable carrier as effective ingredient with this, and preparation can be treated all kinds of preparations of viral disease, cardiovascular and cerebrovascular disease and tumor.
The specific embodiment
Oleum Curcumae is available from Ruian, Zhejiang Province pharmaceutical factory, and quality meets Chinese Pharmacopoeia (1977, two ones P.463) standard.
Vegetable oil can be edible peanut oil, vegetable oil, Semen setariae wet goods, preferably meets the refining of edible vegetable oil of State Standard of the People's Republic of China GB15197-94.
Embodiment 1
Get Oleum Curcumae 100g, mix thoroughly with silica gel with the 300g column chromatography, the dress post after the flushing of 2000ml petroleum ether, again with the 2000ml eluent ethyl acetate, is collected the ethyl acetate part, and 60 ℃ of vacuum reclaim ethyl acetate, and the pale brown color grease of gained is the Oleum Curcumae active constituent.
Detect with the conventional method GC-MS that detects volatile ingredient, wherein do not contain the 6-methene methylene-4,5,6 of poor stability, 7-tetrahydrochysene-3,6-dimethyl-5-isopropenyl-trans-benzofuran composition.(the silica gel column chromatography developing solvent is TLC: petroleum ether-ethyl acetate=9: 1) analyze four brownish red principal spots of demonstration, detect in conjunction with the reference substance comparative measurements through GC-MS, wherein the content of curdione, elemi ketone, (-)-Neocurdione and curcumenol is 30-60%: 15-40%: 1-15%: 1-20% by weight.
Embodiment 2
Get Oleum Curcumae extract 10g of the present invention, vegetable oil 90 g stirring, mixing, filter, make medicinal liquid through 100 mesh sieves.Routine on encapsulating machine is pressed into and contains 1000 of Oleum Curcumae active constituent soft capsules with above-mentioned medicinal liquid and capsule material (glycerol: gelatin: the ratio of water is 1: 3: 3 part by weight).Suggestion children taking dosage is 1-3 grain/sky.
Embodiment 3
Get Oleum Curcumae extract 100g of the present invention, vegetable oil 200g stirring, mixing, filter, make medicinal liquid through 100 mesh sieves.Routine on encapsulating machine is pressed into and contains 1000 of Oleum Curcumae active constituent soft capsules with above-mentioned medicinal liquid and capsule material (glycerol: gelatin: the ratio of water is 1: 3: 3 part by weight).The suggestion taking dose is 1-3 grain/sky.
Embodiment 4
Get Oleum Curcumae extract 200g of the present invention, vegetable oil 100g stirring, mixing, filter, make medicinal liquid through 100 mesh sieves.Routine on encapsulating machine is pressed into and contains 1000 of Oleum Curcumae active constituent soft capsules with above-mentioned medicinal liquid and capsule material (glycerol: gelatin: the ratio of water is 1: 3: 3 part by weight).The suggestion taking dose is 1-2 grain/sky.
Embodiment 5
Get Oleum Curcumae extract 10g, the tween 80 10g of the embodiment of the invention 1, mixing adds the injection water to 1000ml, through filtering with microporous membrane, and sterilization, promptly.
Claims (10)
1, a kind of Oleum Curcumae extract by weight percentage, contains curdione 30-60%, elemi ketone 15-40%, (-)-Neocurdione 1-15%, curcumenol 1-20%.
2, the Oleum Curcumae extract of claim 1 by weight percentage, contains curdione 35-55%, elemi ketone 20-35%, (-)-Neocurdione 2-10%, curcumenol 5-15%.
3, claim 1 or 2 Oleum Curcumae extract is characterized in that: do not contain or be substantially free of 6-methene methylene-4,5,6,7-tetrahydrochysene-3,6-dimethyl-5-isopropenyl-trans-benzofuran.
4, the Oleum Curcumae preparation method of extract of claim 1, Oleum Curcumae and silica gel are mixed thoroughly, the silica gel consumption of mixing Oleum Curcumae is 1-20 a times of Oleum Curcumae, through silica gel column chromatography, eluting solvent be selected from petroleum ether, normal hexane, dichloromethane, ethyl acetate, chloroform, methanol or acetone wherein one or both.
5, the Oleum Curcumae preparation method of extract of claim 4, the silica gel consumption of mixing Oleum Curcumae are 2-10 times of Oleum Curcumae weight, use the petroleum ether eluting earlier, and the reuse eluent ethyl acetate is collected the eluent ethyl acetate part, except that after desolvating, get pale brown color grease.
6, the pharmaceutical composition that contains the Oleum Curcumae extract wherein contains among the claim 1-3 that treats effective dose each Oleum Curcumae extract and pharmaceutically acceptable carrier.
7, the pharmaceutical composition of claim 6 is characterized in that: mainly form capsule 's content by Oleum Curcumae extract 5-200 part and vegetable oil 10-400 part by weight, wrap up in outward by glycerol: gelatin: water is with 1: 2-5: the capsule shell that 2-5 part weight ratio is made.
8, the pharmaceutical composition of claim 7 is characterized in that: capsule 's content mainly is made up of Oleum Curcumae extract 10-100 part and vegetable oil 20-200 part.
9, the pharmaceutical composition of claim 6 is characterized in that: mainly by Oleum Curcumae extract 0.05-3 part, tween 80 0.05-3 part, water for injection are formed for 100 parts by weight.
10, the pharmaceutical composition of claim 9 is characterized in that: be made up of for 100 parts Oleum Curcumae extract 0.1-1 part, tween 80 0.1-1 part, water for injection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410013892 CN1284534C (en) | 2004-01-13 | 2004-01-13 | Aromatic turmeric oil extracts and its preparing process and medicinal composition containing the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410013892 CN1284534C (en) | 2004-01-13 | 2004-01-13 | Aromatic turmeric oil extracts and its preparing process and medicinal composition containing the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1557387A true CN1557387A (en) | 2004-12-29 |
| CN1284534C CN1284534C (en) | 2006-11-15 |
Family
ID=34351154
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410013892 Expired - Fee Related CN1284534C (en) | 2004-01-13 | 2004-01-13 | Aromatic turmeric oil extracts and its preparing process and medicinal composition containing the same |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1284534C (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101709028B (en) * | 2009-09-17 | 2012-05-23 | 海南碧凯药业有限公司 | Method for extracting and separating curdione from oil of zedoary turmeric |
| CN103463564A (en) * | 2013-08-30 | 2013-12-25 | 广州市暨鹏生物科技有限公司 | Externally applied zedoary oil temperature-sensitive gel and preparation method thereof |
| CN109876115A (en) * | 2019-04-16 | 2019-06-14 | 石药集团远大(大连)制药有限公司 | It is a kind of to treat skin trauma, the composition of infectious disease and preparation method and application |
| CN116459210A (en) * | 2023-03-20 | 2023-07-21 | 百正药业股份有限公司 | Industrial production process and detection method of zedoary turmeric oil injection |
-
2004
- 2004-01-13 CN CN 200410013892 patent/CN1284534C/en not_active Expired - Fee Related
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101709028B (en) * | 2009-09-17 | 2012-05-23 | 海南碧凯药业有限公司 | Method for extracting and separating curdione from oil of zedoary turmeric |
| CN103463564A (en) * | 2013-08-30 | 2013-12-25 | 广州市暨鹏生物科技有限公司 | Externally applied zedoary oil temperature-sensitive gel and preparation method thereof |
| CN109876115A (en) * | 2019-04-16 | 2019-06-14 | 石药集团远大(大连)制药有限公司 | It is a kind of to treat skin trauma, the composition of infectious disease and preparation method and application |
| CN109876115B (en) * | 2019-04-16 | 2021-07-30 | 石药集团远大(大连)制药有限公司 | Composition for treating skin wound and infection diseases, preparation method and application |
| CN116459210A (en) * | 2023-03-20 | 2023-07-21 | 百正药业股份有限公司 | Industrial production process and detection method of zedoary turmeric oil injection |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1284534C (en) | 2006-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | Enhanced oral bioavailability and anti-gout activity of [6]-shogaol-loaded solid lipid nanoparticles | |
| US9492402B2 (en) | Formulation of curcuminoids with enhanced bioavailability of curcumin, demethoxycurcumin, bisdemethoxycurcumin and method of preparation and uses thereof | |
| CN1754541A (en) | Steroid saponin pharmaceutical composition and its preparation method and uses | |
| WO2012023146A1 (en) | A pharmaceutical composition of reformulated turmeric extract and a method thereof | |
| US7799353B2 (en) | Pharmaceutical mixture for hepatitis treatment and its preparation method | |
| CN105362340B (en) | A kind of pharmaceutical composition for treating leukaemia and preparation method thereof | |
| CN101143202A (en) | Compound oral administration preparation with protective function to chemical liver injury | |
| CN1284534C (en) | Aromatic turmeric oil extracts and its preparing process and medicinal composition containing the same | |
| CN101849950A (en) | Application of rotundic acid in preparing blood lipid regulating medicines | |
| CN101254217B (en) | Preparation of extract of regeneratabl portion of yew and applications of same for preparing oral anti-cancer medicine | |
| CN102827001A (en) | Ilex kudingcha C.J.Tseng extract | |
| JPS5632418A (en) | Antithrombic agent containing crude drug | |
| CN102370677A (en) | Three-flavor sandalwood preparation and preparation method thereof | |
| CN1961888B (en) | Lyophilized powder injection of baikal skullcap root extract and preparation method thereof | |
| JPH01207233A (en) | Antiarteriosclerotic | |
| CN1981779B (en) | Xanthosine composition and its production method | |
| CN1274684C (en) | Bee glue flavone extract preparation method, pharmaceutical preparation and its new medical uses | |
| CN101785799B (en) | Extract of total triterpenes in dracocephalum moldavica and preparation method and application thereof | |
| CN113925948B (en) | Use of rhizoma Zingiberis recens total extract or its active component, pharmaceutical composition and preparation method | |
| Ziaul Amin et al. | Evaluation of medicinal effects of Gynuraprocumbens leave extracts on oxidative, glycemic, lipidomics, and enzymatic profiles in alloxan-induced diabetic mice | |
| KR100239880B1 (en) | Crude drug composition for treatment and prevention of liver disease | |
| KR0156039B1 (en) | Pharmaceutical composition for hepatic disease | |
| US7150886B2 (en) | Composition for treating diseased liver | |
| KR100249934B1 (en) | Pharmaceutical compositions acting on the circulatory system and process for preparation thereof | |
| JP3183754B2 (en) | Arteriosclerosis inhibitor and composition containing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |